Hunan Warrant Pharmaceutical Co.,Ltd (SHA:688799)
46.48
+0.28 (0.61%)
Feb 4, 2026, 10:15 AM CST
SHA:688799 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,415 | 1,399 | 1,403 | 1,273 | 1,135 | 926.86 |
Other Revenue | 14.06 | 14.06 | 29.33 | 19.2 | 11.95 | 23.76 |
| 1,429 | 1,413 | 1,433 | 1,293 | 1,147 | 950.63 | |
Revenue Growth (YoY) | -1.17% | -1.39% | 10.84% | 12.74% | 20.61% | 15.28% |
Cost of Revenue | 570.63 | 547.62 | 512.15 | 421.91 | 319.33 | 262.39 |
Gross Profit | 858.84 | 865.33 | 920.64 | 870.75 | 827.26 | 688.24 |
Selling, General & Admin | 571.82 | 547.26 | 595.34 | 595.97 | 585.96 | 460.26 |
Research & Development | 153.83 | 158.33 | 103.18 | 88.67 | 70.06 | 63.66 |
Other Operating Expenses | 31.25 | 20.3 | 17.68 | 16.9 | 14.05 | 12.6 |
Operating Expenses | 758.46 | 726.21 | 717.67 | 703.76 | 671.38 | 538.79 |
Operating Income | 100.38 | 139.12 | 202.97 | 166.99 | 155.89 | 149.45 |
Interest Expense | -0.02 | -0.02 | - | - | - | - |
Interest & Investment Income | 98.93 | 16.84 | 16.02 | 15.21 | 5.87 | 0.86 |
Currency Exchange Gain (Loss) | 0.42 | 0.42 | 0.01 | 0.53 | -0.03 | -0.28 |
Other Non Operating Income (Expenses) | -1.97 | -1.1 | -0.24 | -0.24 | -0.51 | 3.55 |
EBT Excluding Unusual Items | 197.75 | 155.27 | 218.76 | 182.5 | 161.21 | 153.58 |
Gain (Loss) on Sale of Investments | -12.91 | -24.31 | - | - | - | -6.29 |
Gain (Loss) on Sale of Assets | -0.03 | -0.03 | -0.48 | -0.89 | -0.39 | 0.01 |
Asset Writedown | -1.5 | - | - | - | - | - |
Legal Settlements | - | - | -5.28 | - | -1.95 | - |
Other Unusual Items | 30.75 | 30.75 | 16.87 | 13.36 | 21.16 | 17.19 |
Pretax Income | 214.06 | 161.68 | 229.88 | 194.96 | 180.03 | 164.48 |
Income Tax Expense | 17.7 | 22.92 | 36.84 | 21.57 | 19.27 | 19.45 |
Earnings From Continuing Operations | 196.37 | 138.76 | 193.04 | 173.39 | 160.76 | 145.03 |
Minority Interest in Earnings | 16.67 | 25.56 | 18.28 | 9.42 | - | - |
Net Income | 213.03 | 164.32 | 211.32 | 182.8 | 160.76 | 145.03 |
Net Income to Common | 213.03 | 164.32 | 211.32 | 182.8 | 160.76 | 145.03 |
Net Income Growth | 0.75% | -22.24% | 15.60% | 13.71% | 10.85% | 25.01% |
Shares Outstanding (Basic) | 132 | 131 | 131 | 131 | 112 | 99 |
Shares Outstanding (Diluted) | 132 | 131 | 131 | 131 | 112 | 99 |
Shares Change (YoY) | 0.19% | -0.03% | 0.19% | 17.21% | 13.60% | 0.14% |
EPS (Basic) | 1.62 | 1.25 | 1.61 | 1.39 | 1.44 | 1.47 |
EPS (Diluted) | 1.62 | 1.25 | 1.61 | 1.39 | 1.44 | 1.47 |
EPS Growth | 0.56% | -22.22% | 15.38% | -2.98% | -2.43% | 24.84% |
Free Cash Flow | -175.01 | -91.65 | 108.68 | 23.8 | 22.63 | 50.91 |
Free Cash Flow Per Share | -1.33 | -0.70 | 0.83 | 0.18 | 0.20 | 0.52 |
Dividend Per Share | 0.429 | 0.429 | 0.643 | 0.643 | 0.500 | - |
Dividend Growth | -33.33% | -33.33% | - | 28.58% | - | - |
Gross Margin | 60.08% | 61.24% | 64.25% | 67.36% | 72.15% | 72.40% |
Operating Margin | 7.02% | 9.85% | 14.17% | 12.92% | 13.60% | 15.72% |
Profit Margin | 14.90% | 11.63% | 14.75% | 14.14% | 14.02% | 15.26% |
Free Cash Flow Margin | -12.24% | -6.49% | 7.58% | 1.84% | 1.97% | 5.36% |
EBITDA | 175.2 | 208.03 | 263.99 | 215.78 | 190.11 | 179.11 |
EBITDA Margin | 12.26% | 14.72% | 18.43% | 16.69% | 16.58% | 18.84% |
D&A For EBITDA | 74.82 | 68.9 | 61.02 | 48.79 | 34.22 | 29.67 |
EBIT | 100.38 | 139.12 | 202.97 | 166.99 | 155.89 | 149.45 |
EBIT Margin | 7.02% | 9.85% | 14.17% | 12.92% | 13.60% | 15.72% |
Effective Tax Rate | 8.27% | 14.17% | 16.03% | 11.06% | 10.70% | 11.83% |
Revenue as Reported | 1,429 | 1,413 | 1,433 | 1,293 | 1,147 | 950.63 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.